These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 16304742)

  • 1. Can the U.S. Food and Drug Administration act against global frauds? The extraterritorial effect of Food and Drug Administration sanctions after Small v. United States.
    O'Reilly J
    Food Drug Law J; 2005; 60(3):347-60. PubMed ID: 16304742
    [No Abstract]   [Full Text] [Related]  

  • 2. Remarks at the Food and Drug Law Institute's 48th Annual Conference.
    Niedelman SM
    Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089
    [No Abstract]   [Full Text] [Related]  

  • 3. Criminalizing knowledge: the perverse implications of the intended use regulations of off-label promotion prosecutions.
    Gentry G
    Food Drug Law J; 2009; 64(3):441-58. PubMed ID: 19999637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why doctors should worry about preemption.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2008 Jul; 359(1):1-3. PubMed ID: 18596269
    [No Abstract]   [Full Text] [Related]  

  • 5. WHO launches taskforce to fight counterfeit drugs.
    Burns W
    Bull World Health Organ; 2006 Sep; 84(9):689-90. PubMed ID: 17128332
    [No Abstract]   [Full Text] [Related]  

  • 6. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract]   [Full Text] [Related]  

  • 7. Life after Riegel: a fresh look at medical device preemption one year after Riegel v. Medtronic, Inc.
    Wartman GJ
    Food Drug Law J; 2009; 64(2):291-311. PubMed ID: 19999286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
    Leghorn J; Brophy E; Rother P
    Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
    [No Abstract]   [Full Text] [Related]  

  • 9. The FDA defense: a prescription for easing the pain of punitive damage awards in medical products liability cases.
    Marthaler AL
    Spec Law Dig Health Care Law; 1997 Sep; (223):9-45. PubMed ID: 10173273
    [No Abstract]   [Full Text] [Related]  

  • 10. The FDA, preemption, and the Supreme Court.
    Glantz LH; Annas GJ
    N Engl J Med; 2008 May; 358(18):1883-5. PubMed ID: 18450601
    [No Abstract]   [Full Text] [Related]  

  • 11. Potential legal barriers to increasing CMS/FDA collaboration: the law of trade secrets and related considerations.
    Wang SS; Smith JJ
    Food Drug Law J; 2003; 58(4):613-27. PubMed ID: 15027453
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drug counterfeiting and counter measures. Study by the Hungarian National Alliance Against Drug Counterfeiting].
    Psychiatr Hung; 2009; 24(3):205-14. PubMed ID: 20017282
    [No Abstract]   [Full Text] [Related]  

  • 13. Watch out for: fake patients seeking treatment in order to obtain drugs.
    Hosp Secur Saf Manage; 1993 Jun; 14(2):10-3. PubMed ID: 10126554
    [No Abstract]   [Full Text] [Related]  

  • 14. Implications of international drug approval systems on confidentiality of business secrets in the U.S. pharmaceutical industry.
    O'Reilly JT
    Food Drug Law J; 1998; 53(1):123-32. PubMed ID: 11795328
    [No Abstract]   [Full Text] [Related]  

  • 15. As voters pass pot measures, grass grows under plans' feet.
    Dalzell MD
    Manag Care; 1999 Jan; 8(1):15-6. PubMed ID: 10346095
    [No Abstract]   [Full Text] [Related]  

  • 16. Walking the drug regulatory tightrope.
    Dove A
    Nat Biotechnol; 2003 May; 21(5):495-8. PubMed ID: 12721571
    [No Abstract]   [Full Text] [Related]  

  • 17. Ejecting the FDA from the courtroom.
    Lancet; 2004 Aug 21-27; 364(9435):638. PubMed ID: 15325808
    [No Abstract]   [Full Text] [Related]  

  • 18. Medical device preemption after Medtronic, Inc. v. Lohr.
    Neraas MB
    Food Drug Law J; 1996; 51(4):619-29. PubMed ID: 11797731
    [No Abstract]   [Full Text] [Related]  

  • 19. Forces reshaping the performance and contribution of the U.S. medical device industry.
    Benson JS
    Food Drug Law J; 1996; 51(2):331-6. PubMed ID: 11822326
    [No Abstract]   [Full Text] [Related]  

  • 20. U.S. medical device reporting: who is responsible?
    Donawa M
    Med Device Technol; 2005 Apr; 16(3):27-9. PubMed ID: 15871421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.